Histogen Inc. (HSTO)
OTC PINK OTC PINK Primary Summary
Histogen Inc. (HSTO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Histogen Inc. ever had a stock split?
Histogen Inc. Profile
| Biotechnology Industry | Healthcare Sector | Susan A. Knudson CEO | OTC PINK Exchange | 43358Y202 CUSIP |
| US Country | 7 Employees | - Last Dividend | 3 Jun 2022 Last Split | 25 Jul 2013 IPO Date |
Overview
Histogen Inc. is a clinical-stage therapeutics company committed to the development of innovative treatments focusing on protecting the body's natural process to restore immune function. Their research is centered around developing small molecule pan-caspase and caspase selective inhibitors. Founded in 2007 and headquartered in San Diego, California, Histogen aims to address the critical medical needs in various therapeutic areas, particularly in infectious diseases and inflammatory conditions.
Products and Services
- Emricasan
A small molecule pan-caspase inhibitor, Emricasan is primarily targeted for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and other infectious diseases. By focusing on caspase inhibition, Emricasan aims to mitigate the processes leading to cellular apoptosis and inflammation, making it a potential therapeutic agent for managing infections that have a significant impact on immune health.
- CTS-2090 and CTS-2096
As part of Histogen's preclinical pipeline, CTS-2090 and CTS-2096 are novel, selective small molecule inhibitors of caspase-1. These candidates are being developed for the treatment of various inflammatory diseases. Caspase-1 is pivotal in the process of inflammation, playing a crucial role in the activation of cytokines such as interleukin-1β (IL-1β). By targeting caspase-1, these molecules hold promise for controlling and treating diseases where inflammation is a key underlying factor.
